Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

Inclusion Criteria:

* Participants are 18-55 years old.
* Participants BMI is ≥30 kg/m2 - this BMI requirement is due to our research aims.
* Participants have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
* Participants are not pregnant or expecting to become pregnant (females only). •Participants are not postmenopausal (females only).
* Participants have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
* Participants have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis).
* Participants do not regularly take anti-inflammatory drugs (more than 2x week) and are willing to suspend use of these medications for 3 days leading up to in-lab visits.
* Participants do not take weight-loss medications (e.g., Ozempic, Wegovy).
* Participants do not use tobacco products or any illicit drugs.
* Participants have not used antibiotics or probiotics in the last month.
* Participants do not have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
* Participants do not have a pacemaker.
* Participants are able to lie on their back (supine position) in the dark for at least 10 minutes (related to vascular measurements).

Exclusion Criteria:

* Participants are not 18-55 years old.
* Participants BMI is not ≥30 kg/m2 - this BMI requirement is due to our research aims.
* Participants do not have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
* Participants are pregnant or expecting to become pregnant (females only).
* Participants are postmenopausal (females only).
* Participants have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
* Participants have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis). •Participants regularly take anti-inflammatory drugs (more than 2x week) and are not willing to suspend use of these medications for 3 days leading up to in-lab visits.
* Participants take weight-loss medications (e.g., Ozempic, Wegovy).
* Participants use tobacco products or any illicit drugs.
* Participants have used antibiotics or probiotics in the last month.
* Participants have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
* Participants have a pacemaker.